Dr. Ailawadhi on the Rationale for Evaluating Lisaftoclax in CLL

Video

In Partnership With:

Sikander Ailawadhi, MD, discusses the rationale for evaluating lisaftoclax in chronic lymphocytic leukemia in an early phase 1 study.

Sikander Ailawadhi, MD, professor of medicine, consultant, Division of Hematology/Oncology, Department of Internal Medicine, consultant, Department of Cancer Biology, lead, International Cancer Center, Mayo Clinic, discusses the rationale for evaluating lisaftoclax (APG-2575) in chronic lymphocytic leukemia (CLL) in an early phase 1 study (NCT03537482).

Venetoclax (Venclexta), a first-generation BCL-2 inhibitor, is FDA approved for the treatment of several lymphoid and myeloid malignancies, including CLL.The rationale for the phase 1 trial was to continue exploring the role of BCL-2 inhibitors in CLL with the next-generation agent lisaftoclax, Ailawadhi explains. Lisaftoclax was hypothesized to be more refined, more active, and better tolerated compared with venetoclax in this patient population, Ailawadhi says. 

Lisaftoclax has a distinct pharmacokinetic and pharmacodynamic profile in which it affects but does not irreversibly bind to BCL-2 to cause prolonged adverse effects, Ailawadhi adds. Overall, lisaftoclax demonstrated similarefficacy to venetoclax with a different, safer toxicity profile, Ailawadhi concludes.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD